Supporting Statement
For
Administrative Detention and Banned Medical Devices
21 CFR 800.55(g)(1) & (2), 800.55(k), and 895.22
OMB Control Number 0910-0114

A. JUSTIFICATION

1. Circumstances Making the Collection of Information Necessary

The Food and Drug Administration (FDA) has the statutory authority under section 304(g) of the Federal Food, Drug and Cosmetic Act [21 U.S.C. 334(g)] (the Act), where officers or employees duly designated by the Secretary (FDA investigators) may detain devices during establishment inspections which are believed to be adulterated or misbranded. On March 9, 1979, FDA issued, under 21 CFR 800.55, a final regulation on Administrative Detention Procedures (44 FR 13234), under section 304(g) of the Act, which includes, among other things, certain reporting requirements [800.55(g)(1) & (2)] and recordkeeping requirements (800.55(k)]. Under § 800.55(g), an appellant of a detention order must show documentation of ownership if devices are detained at a place other than that of the appellant. Under § 800.55(k), the owner or other responsible person must supply records about how the devices may have become adulterated or misbranded, as well as records of distribution of the detained devices. These recordkeeping requirements for administrative detentions allow FDA to trace devices for which the detention period expired before a seizure is accomplished or injunctive relief is obtained.

FDA also has the statutory authority under section 516 of the Act [21 U.S.C. 360f] to ban devices that present substantial deception, or unreasonable and substantial risk of illness or injury, or unreasonable, direct, and substantial danger to the health of individuals. The final regulation for Banned Devices (44 FR 29221), which issued on May 18, 1979, (21 CFR Part 895), contained certain reporting requirements, 21 CFR 895.21(d) and 895.22(a).

FDA is requesting approval from the Office of Management and Budget (OMB) for the following requirements:

21 CFR 800.55(g)(1) and (2) - Administrative Detention Reporting

A person who would be entitled to claim the devices, if seized may appeal a detention order by submitting a written request to the FDA District director in whose district the devices are located. This written appeal could include a request for an informal hearing as defined in section 201(y) of the Act. In some cases, the appellant must include documents showing that that person has the legal right to appeal this order.

21 CFR 800.55(k) - Administrative Detention Recordkeeping
The firm shall have, or establish, and maintain records relating to how the detained devices may have become adulterated or misbranded, records on any distribution of the devices before and after the detention period, records on the correlation of any in-process detained devices that are put in final form, records of any changes in, or process of, the devices permitted under the detention order, and records of any movement of the detained devices.

21 CFR 895.22(a) - Banned Devices Reporting

A manufacturer, distributor, or importer of a device may be required to submit to the FDA all relevant and available data and information to enable the Commissioner to determine whether the device presents substantial deception, unreasonable, direct, and substantial danger to the health of individuals.

2. Purpose and Use of the Information

Data and information collected under the reporting and recordkeeping requirements of the administrative detention and banned device regulations are used by the Agency to determine if the devices which are believed to be adulterated and/or misbranded; present substantial deception, unreasonable and substantial risk of illness or injury, or unreasonable, direct, and substantial danger to the health of individuals are removed from the marketplace. If the FDA did not have these regulations, it would not have access to certain types of data and information which industry possesses. Thus, the collection of this information enables the Agency to perform its mission of consumer protection.

When a detention order is put into place, the Agency must know if any other devices which would be subject to the order, were distributed prior to that time to assure that those devices are removed from the marketplace and do not cause any adverse effects. The recordkeeping requirement of the Administrative Detention regulation gives FDA the authority to obtain distribution information which the Agency might not otherwise have. This recordkeeping requirement may also provide FDA with an answer for how the devices became adulterated and/or misbranded.

FDA has only used the Banned Device regulation once to require importers of prosthetic hair fibers to supply the Agency with data and information relating to this product. Information obtained under the reporting requirements of this regulation, which would not otherwise be available to the Agency, convinced FDA that this device should be banned from commercial distribution. FDA may use this regulation in the future in regards to another device if the Commissioner believes that more information is necessary for the Agency to determine whether the device presents a substantial deception, an unreasonable and substantial risk of illness or injury, or unreasonable, direct and substantial danger to the health of individuals. The FDA would then require that the manufacturer, distributor, or importer submit all relevant and available data and information. After consulting with the appropriate classification panel, FDA may initiate a proceeding to ban the device by publishing a proposed regulation in the FEDERAL REGISTER. After affording all
interested persons an opportunity for an informal hearing on the proposal, FDA will affirm,
modify, or revoke the proposed regulation. If the proposal is affirmed or modified, the
Agency will publish a final regulation banning the device.

3. **Use of Information Technology and Burden Reduction**

In the **Federal Register** of March 20, 1997, FDA issued a final regulation (21 CFR Part
11) (Attachment 6) that would, under certain circumstances, permit the agency to accept
electronic signatures and handwritten signatures executed to electronic records as generally
equivalent to paper records and handwritten signatures executed on paper. These
regulations would apply to records, submitted in electronic form, that are required in Title
keeping and reporting submissions to FDA remains voluntary. The intended effect of this
regulation is to permit use of electronic technologies in a manner that is consistent with
FDA's overall mission and that preserves the integrity of the agency's enforcement
activities.

There are no technical or legal obstacles to the collection of information with regard to
devices affected under these regulations. Some firms are now using computers to store
information under the recordkeeping requirements of these regulations which has led to a
decrease of industry's time. Additionally, improved technologies, such as, CAD-CAM
(Computer Assisted Drawing - Computer Assisted Manufacturing), lasers, photo-etching,
etc., are being used to assist manufacturers in making changes to the devices, or the device
labeling, which would result in compliance and eliminate the need to ban a device.

4. **Efforts to Identify Duplication and Use of Similar Information**

FDA is the only federal agency responsible for regulating medical devices. Such regulation
extends to include the administrative detention of adulterated and/or misbranded devices
and the banning of any device that presents a substantial deception, unreasonable and
substantial risk of illness or injury, or unreasonable, direct, and substantial danger to the
health of individuals. As such, there is no duplication of effort or requirements.

5. **Impact on Small Businesses or Other Small Entities**

These regulations apply equally to all firms, regardless of the size of the establishment, if
the product in question is believed to be adulterated or misbranded, in the case of
administrative detentions, or presents an unreasonable risk or deception to the public, in the
case of banning a device. FDA established a Division of Small Manufacturers Assistance
(DSMA), as required by the 1976 Amendments to the Act., and in addition, is providing a
variety of information about the safe manufacture of medical devices on the FDA’s Internet

DSMA provides technical and non-financial assistance to firms through a comprehensive
program that includes onsite inspections (when requested by the manufacturer),
participating in and presenting conferences, workshops, seminars on the application and interpretation of relevant regulations, consulting with individual firms/sponsors, and development and dissemination of educational material. DSMA's staff is available to respond to questions, as is CDRH staff, at anytime via a toll free telephone number established to facilitate this communication link.

6. Consequences of Collecting the Information Less Frequently

The collection of data and information under these regulations is conducted on a very infrequent basis and only as necessary. Thus, FDA could not adequately protect the public health if this information were conducted less frequently.

7. Special Circumstances Relating to the Guidelines of 5 CFR 1320.5

The requirements of the administrative detention and banned device regulations are consistent with 5 CFR 1320.5 and applicable guidelines.

8. Comments in Response to the Federal Register Notice and Efforts to Consult Outside Agency

Notice has been published in the Federal Register on March 31, 2000 (65 FR 17282) soliciting comments on this information collection prior to its submission to the Office of Management and Budget (OMB) as required by 5 CFR 1320.8(d) (see Attachment 5). No significant comments were received.

FDA’s experience with the administrative detention reporting and recordkeeping requirements have shown that most establishments maintain records required by good manufacturing practice regulations. A review of all forty-nine (49) administrative detentions that have been enforced in approximately nineteen years prior to this reporting period indicates that this regulation has not been an unreasonable burden on industry. In most cases, the devices were either seized or voluntarily corrected (reconditioned, relabeled, or destroyed) within the period of detention or shortly thereafter.

In an effort to determine the current burden on industry, FDA spoke with Dr. Nadeem M. Muna, President, Immuno Diagnostic Products, Inc. (North Salt Lake City, Utah, (801) 298-7535), at the time of the last reporting period, regarding the administrative detention of immunofluorescent test kits. FDA has taken only one administrative detention during this reporting period, and has not solicited any further comments from outside the Agency.

FDA has limited experience with the regulations for Banned Devices in that it was only used once to ban prosthetic hair fibers (49 FR 1177). FDA has not solicited any further comment from outside of the Agency regarding banning actions.

9. Explanation of Any Payment or Gift to Respondents
FDA will not provide any payments or gifts to respondents of this information collection.

10. Assurances of Confidentiality Provided to Respondent

Information provided to, or obtained by, FDA is subject to release under the Freedom of Information Act (5 U.S.C. 552) and the implementing regulations contained in 21 CFR Parts 20 and 21.

11. Justification for Sensitive Questions

The information required in this information collection does not include questions about sexual behavior, attitude, religious beliefs, or any other matters which are commonly considered private or sensitive in nature.

12. Estimates of Hour Burden Including Annualized Hourly Costs

FDA estimates the burden of this collection of information as follows:
Table 5.--Estimated Annual Reporting Burden

<table>
<thead>
<tr>
<th>21 CFR Section</th>
<th>No. of Respondents</th>
<th>Annual Frequency per Response</th>
<th>Total Annual Responses</th>
<th>Hours per Response</th>
<th>Total Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>800.55(g)(1) and (2)</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>25</td>
<td>25</td>
</tr>
<tr>
<td>895.22(a)</td>
<td>26</td>
<td>1</td>
<td>26</td>
<td>16</td>
<td>416</td>
</tr>
<tr>
<td>TOTALS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>441</td>
</tr>
</tbody>
</table>

There are no capital costs or operating and maintenance costs associated with this collection of information.

Table 6.--Estimated Annual Recordkeeping Burden

<table>
<thead>
<tr>
<th>21 CFR Section</th>
<th>No. of Recordkeepers</th>
<th>Annual Frequency per Recordkeeping</th>
<th>Total Annual Records</th>
<th>Hours per Recordkeeper</th>
<th>Total Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>800.55(k)</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>TOTALS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>461</td>
</tr>
</tbody>
</table>

There are no capital costs or operating and maintenance costs associated with this collection of information.

One administrative detention action was taken over the past 3 years. Each administrative detention will have varying amounts of data and information that must be maintained.

FDA's estimate of the burden under the administrative detention provision is based on FDA's discussion with a firm whose devices had been detained during the past reporting period.

Historically, FDA has had very few or no annual responses for this information collection. However, FDA normally reports one response per year. FDA is anticipating a banning action in Fiscal Year 2000 that will involve 26 firms.

Because the amount of recordkeeping required for each administrative detention action will vary according to the nature of the device, the quantity detained, and its disposition, it is impossible to give an estimated annualized cost that would be accurate for each respondent. For example, the cost of maintaining this information for a warehouse, where the device was detained and voluntarily destroyed, would be much less than for a manufacturer who slowly reconditions and releases the device over a period of time. The warehouse could fulfill the recordkeeping requirements of this regulation by maintaining a copy of the shipping record showing how many units were received, while the manufacturer may have to maintain records re: components, manufacture, quality control, shipping, complaint or failure investigation, recall, reconditioning, new quality control, and new shipping. Thus, the estimated annualized cost for each respondent could range from several dollars to several hundreds (perhaps thousands) in a small number of cases. Based upon FDA's history with administrative detentions over the past three years, the Agency believes that
the total cost to industry is under $2,000.00 per year.

In a previous reporting period, a large firm (Life Design Systems) reported that they spent approximately $4,000.00 in recordkeeping re: reconditioning/testing or destruction of product. However, it should be noted that this product was seized and that reconditioning and destruction did not start until after a Consent Decree was entered into. Thus, the firm would have spent $4,000.00 on recordkeeping even if the product was not administratively detained. The estimated cost for a respondent to have a hearing to appeal an administrative detention could be several thousand dollars or more, depending upon whether an attorney is involved and the documented evidence. Life Design Systems decided to appeal the administrative detention, hired a well-known law firm, hired a research firm to find case law, paid the court reporter for the transcripts, had several of their people on hand during a rather lengthy hearing, and reported that they spent over $80,000.00 on the appeal. FDA believes this to be an atypical amount and that no other appeal has cost nearly as much.

13. **Estimate of Other Total Annual Cost Burden to Respondents or Recordkeepers**

There are no capital costs and or operating and maintenance costs for this information collection.

14. **Annualized Cost to the Federal Government**

The annualized cost to the Federal Government, which is based upon approximately 0.1 staff years at $89,705 per year amounts to approximately $9,000. Additional costs will be incurred if the administrative detention is appealed and a hearing is conducted to determine if the Agency had cause to take such an action. This hearing must be conducted in accordance with 21 CFR 800.55(g)(3) and has the potential of costing the Agency thousands of dollars. The cost to the Federal Government for one appeal hearing, which is based upon the staff hours necessary to review and prepare for a hearing, plus the cost of flying out General Counsel attorneys to the district office where the devices were detained, is approximately $3,000.

During the approximately 19 years that the banned device regulation has been in effect, FDA has only used it once to ban prosthetic hair fibers (21 CFR 895.101.) For this reason, and because situations resulting in banning a device are so reactive and therefore difficult to predict, it is difficult to estimate the cost to the Federal Government imposed by this regulation.

15. **Explanation for Program Changes or Adjustments**

There is anticipated to be an increase in the annual number of banning actions for FY2000. Consequently, this information collection is reflecting that the burden upon industry will increase, as FDA anticipates a banning action that will involve 26 firms.
16. **Plans for Tabulation and Publication and Project Time Schedule**

The collection of information under these regulations will not be published for statistical use.

17. **Reason(s) Display of OMB Expiration Date is Inappropriate**

FDA is not seeking an exemption from the requirement to display the effective date.

18. **Exception to Certification for Paperwork Reduction Act Submissions**

The requirements of the administrative detention and banned device regulations are consistent with 5 CFR 1320.9. There are no exceptions to the certification statement in item 19 of OMB Form 83-I.

19. **Certification for Paperwork Reduction Act Submissions**

**B. Collection of Information Employing Statistical Methods**

There are no statistical methods being employed in this collection of information.

**List of Attachments to Supporting Statement:**

- **Attachment 1** - Federal Food, Drug, and Cosmetic Act, Section 304 [21 U.S.C. 334(g)]
- **Attachment 2** - 21 CFR Part 800.55
- **Attachment 3** - Federal Food, Drug, and Cosmetic Act, Section 516 [21 U.S.C. 360(f)]
- **Attachment 4** - 21 CFR Part 895
- **Attachment 5** - Federal Register 60 day Notice Soliciting Comments on Administrative Detention and Banned Medical Devices.
- **Attachment 6** - 21 CFR Part 11.